Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In breast cancer, the identification of accurate predictors of tumor response to neoadjuvant chemotherapy is of key importance, but none of the critical markers have been validated to date. We attempted to identify potent marker genes genome-wide, and we developed a prediction model for individual response to epirubicin (EPI)/cyclophosphamide (CPM) combination chemotherapy (EC).
From 10 human breast cancer cell lines, genes whose expression levels correlated with cytotoxicities of EPI and CPM were chosen through comprehensive gene expression analysis followed by correlation–confirmation study of the quantified expression levels analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR).
We finally selected a total of 4 genes (ANXA1 and PRKCA for EPI; DUSP2 and SERPINA3 for CPM) as reliable prediction markers. Using quantified expression data of genes in 18 tumor samples, we performed multiple linear regression analysis to establish the best linear model that could convert the quantified expression data to show tumor response to the EC therapy (the ratio of tumor size to the baseline, %). Outliers were identified by referring to the value of AIC (Akaike’s information criterion) for each sample (AIC/sample) or checking residuals graphically. The multiple linear regression analysis of the selected genes yielded 2 highly predictive formulae for the tumor response: one used all of the genes except SERPINA3 (R = 0.8348, AIC/sample = 4.9182) and the other used all of the 4 genes (R = 0.8224, AIC/sample = 5.0730).
A study to validate the predictive values of the selected 4 genes is now planned, along with research to determine their functional roles.
- Horiguchi J. New trends in primary systemic therapy for breast cancer. Breast Cancer 2010; Epub ahead of print, doi:10.1007/s12282-010-0243-4.
- Benson, JR, Jatoi, I, Keisch, M, Esteva, FJ, Makris, A, Jordan, VC (2009) Early breast cancer. Lancet 373: pp. 1463-1479 CrossRef
- Kinoshita T. Preoperative therapy: recent findings. Breast Cancer 2010; Epub ahead of print doi:10.1007/s12282-010-0227-4.
- Untch, M, Minckwitz, G (2009) Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 11: pp. 203 CrossRef
- Colleoni, M, Viale, G, Goldhirsch, A (2009) Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting. Breast 18: pp. S137-S140 CrossRef
- Beasley, GM, Olson, JA (2010) What’s new in neoadjuvant therapy for breast cancer?. Adv Surg 44: pp. 199-228 CrossRef
- Gluz, O, Liedtke, C, Gottschalk, N, Pusztai, L, Nitz, U, Harbeck, N (2009) Triple-negative breast cancer—current status and future directions. Ann Oncol 20: pp. 1913-1927 CrossRef
- Shenoy, HG, Peter, MB, Masannat, YA, Dall, BJ, Dodwell, D, Horgan, K (2009) Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer. Surg Oncol 18: pp. 65-71 CrossRef
- Liu, SV, Melstrom, L, Yao, K, Russell, CA, Sener, SF (2010) Neoadjuvant therapy for breast cancer. J Surg Oncol 101: pp. 283-291 CrossRef
- Munro, AF, Cameron, DA, Bartlett, JM (2010) Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene 29: pp. 5231-5240 CrossRef
- Bartlett, JM, Munro, AF, Dunn, JA, McConkey, C, Jordan, S, Twelves, CJ (2010) Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 11: pp. 266-274 CrossRef
- Marsh, S, Liu, G (2009) Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy. Adv Drug Deliv Rev 61: pp. 381-387 CrossRef
- Baek, HM, Chen, JH, Nie, K, Yu, HJ, Bahri, S, Mehta, RS (2009) Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 251: pp. 653-662 CrossRef
- Tanioka, M, Shimizu, C, Yonemori, K, Yoshimura, K, Tamura, K, Kouno, T (2010) Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. Br J Cancer 103: pp. 297-302 CrossRef
- Chuthapisith, S, Eremin, JM, Eremin, O (2008) Predicting response to neoadjuvant chemotherapy in breast cancer: molecular imaging, systemic biomarkers and the cancer metabolome (Review). Oncol Rep 20: pp. 699-703
- Tanaka, T, Tanimoto, K, Otani, K, Satoh, K, Ohtaki, M, Yoshida, K (2004) Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 11: pp. 617-626 CrossRef
- Komatsu, M, Hiyama, K, Tanimoto, K, Yunokawa, M, Otani, K, Ohtaki, M (2006) Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther 5: pp. 767-775 CrossRef
- Shimokuni, T, Tanimoto, K, Hiyama, K, Otani, K, Ohtaki, M, Hihara, J (2006) Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data. Int J Oncol 28: pp. 1153-1162
- Fumoto, S, Shimokuni, T, Tanimoto, K, Hiyama, K, Otani, K, Ohtaki, M (2008) Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int J Oncol 32: pp. 413-423
- Nishiyama, M, Eguchi, H (2009) Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv Drug Deliv Rev 61: pp. 402-407 CrossRef
- Staunton, JE, Slonim, DK, Coller, HA, Tamayo, P, Angelo, MJ, Park, J (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 98: pp. 10787-10792 CrossRef
- McLeod, HL, Evans, WE (2001) Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 41: pp. 101-121 CrossRef
- Rousseeuw, PJ (1984) Least median of squares regression. J Am Stat Assoc 79: pp. 871-880 CrossRef
- Turaga, K, Acs, G, Laronga, C (2010) Gene expression profiling in breast cancer. Cancer Control 17: pp. 177-182
- Perou CM, Børresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol 2010; Epub ahead of print doi:10.1101/cshperspect.a003293.
- Ou, K, Yu, K, Kesuma, D, Hooi, M, Huang, N, Chen, W (2008) Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. J Proteome Res 7: pp. 1518-1528 CrossRef
- Bergman, PJ, Gravitt, KR, Ward, NE, Beltran, P, Gupta, KP, O’Brian, CA (1997) Potent induction of human colon cancer uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-alpha (PKC-alpha) pseudosubstrate peptides through a P-glycoprotein-independent mechanism. Invest New Drugs 15: pp. 311-318 CrossRef
- Gravitt, KR, Ward, NE, Fan, D, Skibber, JM, Levin, B, O’Brian, CA (1994) Evidence that protein kinase C-alpha activation is a critical event in phorbol ester-induced multiple drug resistance in human colon cancer cells. Biochem Phamacol 48: pp. 375-381 CrossRef
- Chen, Y, Yu, G, Yu, D, Zhu, M (2010) PKCalpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1. J Exp Clin Cancer Res 29: pp. 104 CrossRef
- Bermudez, O, Pagès, G, Gimond, C (2010) The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 299: pp. C189-C202 CrossRef
- Baker, C, Belbin, O, Kalsheker, N, Morgan, K (2007) SERPINA3 (aka alpha-1-antichymotrypsin). Front Biosci 12: pp. 2821-2835 CrossRef
- Cimino, D, Fuso, L, Sfiligoi, C, Biglia, N, Ponzone, R, Maggiorotto, F (2008) Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues. Int J Cancer 123: pp. 1327-1338 CrossRef
- Pohl, A, Lurje, G, Manegold, PC, Lenz, HJ (2009) Pharmacogenomics and -genetics in colorectal cancer. Adv Drug Deliv Rev 61: pp. 375-380 CrossRef
- Ruzzo, A, Graziano, F, Kawakami, K, Watanabe, G, Santini, D, Catalano, V (2006) Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 24: pp. 1883-1891 CrossRef
- Lu, JW, Gao, CM, Wu, JZ, Cao, HX, Tajima, K, Feng, JF (2006) Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet 51: pp. 155-160 CrossRef
- Ichikawa, W, Takahashi, T, Suto, K, Shirota, Y, Nihei, Z, Shimizu, M (2006) Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 119: pp. 1927-1933 CrossRef
- Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels
Volume 19, Issue 1 , pp 37-45
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Breast cancer
- Response prediction
- Neoadjuvant chemotherapy
- Marker gene
- Industry Sectors
- Author Affiliations
- 1. Department of Breast Oncology, International Medical Center, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan
- 2. Research Institute for Development Therapeutics, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1298, Japan